Although several clinical trials involving targeted therapies for HCC have not yielded tangible clinical benefit, these therapeutic targets, including c-Met, TGF-β, and FGFR, remain relevant to current and future investigations involving novel agents and modified patient selection and study design. The gene discussed is MET; the disease is hepatocellular carcinoma.